Project Grant HT94252410521
Award Date 7/1/24
Completion Date 6/30/26
Dollars Obligated $708K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The Department of the Army Medical Command awarded a $884,997 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program. The three-year grant will fund research to intervene in the TP53 pathway phosphatome in pediatric high-grade gliomas. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research that investigates medical solutions...
- The Defense Health Agency has awarded a $1,483,340 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) in Boston, MA. The grant, with a performance period from June 1, 2024 to May 31, 2028, will fund research to harness extracellular domain (ECD) cleavage of anaplastic lymphoma kinase (ALK) for immunotherapy against neuroblastoma. As a non-profit hospital and cancer research center, DFCI will...
- The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
- The Defense Health Agency has awarded a $178,000 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct research on "DISSECTING THE DIFFERENCE IN THE PATHOGENESIS AND IMMUNE MICROENVIRONMENT OF PEDIATRIC AND ADULT OSTEOSARCOMA". This research project falls under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform healthcare for the U.S. military and the public. DFCI, a non-profit hospital and cancer...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
- The federal Project Grant award of $2,136,000.00 was provided by the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant supports research aimed at understanding and therapeutically targeting treatment-emergent neuroendocrine prostate cancer. As a leading academic medical research institution, DFCI will leverage its expertise in oncology, immunology, molecular...
- The Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $778,092.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to advance preclinical studies of a dual-targeted fine-tuned immune-restoring (DFIR) CAR-T cell therapy for the treatment of high-grade serous ovarian cancer. This research aims to develop innovative immunotherapeutic approaches to achieve cures for this aggressive form of ovarian cancer. DFCI, a...
- The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
- The Defense Health Agency awarded a $524,664 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) through the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, which runs from December 1, 2024 to November 30, 2026, will fund research into the "Mechanisms of Irisin-Induced Cognitive Benefit in PD." DFCI, a prestigious non-profit cancer research center in Boston, will leverage its expertise in areas like oncology, immunology, and...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...